Business
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its targeted full enrollment of 435 patients in the registration-enabling Phase 2/3 trial (OptimUM-02) evaluating darovasertib, the company's investigational oral protein kinase C (PKC) inhibitor, in combination with Pfizer's crizotinib, an oral c-MET inhibitor, in first line (1L) HLA*A2-negative metastatic uveal melanoma (mUM). IDEAYA expects to report median progression-free
About this update from Pfizer, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Targeted enrollment of 435 patients to enable potential full approval filing has been completed in OptimUM-02 trial","length":115,"tagName":"p"}]},{"val":[{"type":"text","content":"Topline data, including median PFS, are expected in 1Q 2026 to support a potential accelerated approval filing in the United States","length":131,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":246,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its targeted full enrollment of 435 patients in the registration-enabling Phase 2/3 trial (OptimUM-02) evaluating darovasertib, the company's investigational oral protein kinase C (PKC) inhibitor, in combination with Pfizer's crizotinib, an oral c-MET inhibitor, in first line (1L) HLA*A2-negative metastatic uveal melanoma (mUM). IDEAYA expects to report median progression-free survival (PFS) data from this trial in the first quarter 2026 to support a potential accelerated approval filing in the United States. Median overall survival (mOS) data from OptimUM-02, once available, will be used to support a potential full approval filing. Metastatic uveal melanoma is a rare, aggressive form of ocular cancer with limited treatment options and historically poor survival outcomes.","length":970,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/IDEAYA Biosciences, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/IDEAYA Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":263,"url":"https://media.zenfs.com/en/prnewswire.com/74efd2e2f7cc28d3a6ce5efb40fb6e7d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7kIIgx9lBKLOOeuEoOJXpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ2NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/74efd2e2f7cc28d3a6ce5efb40fb6e7d","width":400,"height":263}},"href":"https://mma.prnewswire.com/media/820568/IDEAYA_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We are very pleased to announce that we have achieved the target enrollment to enable potential full approval filing in our Phase 2/3 registration-enabling trial of darovasertib in combination with crizotinib in first-lin...